Table 3

Model outcomes for costs, survival (life-years) and quality-adjusted life-years (QALYs), undiscounted and discounted (including benefit of reduction in breast cancer risk from premenopausal risk-reducing salpingo-oophorectomy (RRSO))

Breast cancer incidenceOvarian cancer incidenceSurvivalDiscounted survivalCostDiscounted costQALYDiscounted QALY
10% risk
 No RSSO0.1290.10041.521.26114290441.121.1
 RRSO0.0800.00642.8021.465705.814433.9642.3121.36
 Difference0.0490.0941.000.26−40815301.210.30
 ICER (£/QALY)−3385031
8% risk
 No RRSO0.1290.08041.6821.255606263741.321.1
 RRSO0.0800.00542.4921.465675.524418.142.3221.37
 Difference0.0490.0750.810.217017811.00.2
 ICER (£/QALY)717370
6% risk
 No RRSO0.1290.06041.8821.305098236941.621.2
 RRSO0.080.00442.5021.465645.234402.2442.3421.37
 Difference0.0490.0560.620.1654720330.80.2
 ICER (£/QALY)72611337
5% risk
 No RRSO0.12900.050041.9821.334844223641.7021.22
 RRSO0.0800.018342.5121.465630439442.3521.37
 Difference0.04900.03170.52940.136078621590.64130.1481
 ICER (£/QALY)122614573
4% risk
 NO RRSO0.1290.04042.0821.364590210241.821.3
 RRSO0.0800.00242.5121.475614.944836.3942.3521.37
 Difference0.0490.0380.440.11102522840.50.117
 ICER (£/QALY)194019 536
2% risk
 NO RRSO0.1290.02042.2821.414082183442.121.3
 RRSO0.080.0042.5321.475584.644370.5342.3721.38
 Difference0.0490.0190.250.06150325360.30.055
ICER (£/QALY)496946 480
  • ICER, incremental cost-effectiveness ratio (£/QALY), QALY- quality adjusted life-year, RRSO- risk reducing salpingo-oophorectomy.